Celgene Corporation (NASDAQ:CELG) Director Gilla Kaplan sold 9,250 shares of the firm’s stock in a transaction that occurred on Tuesday, September 12th. The shares were sold at an average price of $141.56, for a total transaction of $1,309,430.00. Following the completion of the sale, the director now owns 85,551 shares in the company, valued at approximately $12,110,599.56. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.
Gilla Kaplan also recently made the following trade(s):
- On Wednesday, August 2nd, Gilla Kaplan sold 7,500 shares of Celgene Corporation stock. The shares were sold at an average price of $134.52, for a total transaction of $1,008,900.00.
Shares of Celgene Corporation (NASDAQ CELG) opened at 142.04 on Friday. Celgene Corporation has a 52-week low of $96.93 and a 52-week high of $142.69. The company has a market capitalization of $111.12 billion, a P/E ratio of 43.99 and a beta of 1.89. The stock’s 50 day moving average is $134.97 and its 200 day moving average is $127.46.
Celgene Corporation (NASDAQ:CELG) last issued its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.82 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.61 by $0.21. The company had revenue of $3.27 billion during the quarter, compared to analyst estimates of $3.23 billion. Celgene Corporation had a net margin of 21.35% and a return on equity of 68.51%. Celgene Corporation’s quarterly revenue was up 18.7% compared to the same quarter last year. During the same period last year, the business earned $1.44 EPS. Equities analysts expect that Celgene Corporation will post $7.33 EPS for the current year.
ILLEGAL ACTIVITY WARNING: This report was first reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this report on another website, it was illegally copied and reposted in violation of US & international trademark and copyright laws. The original version of this report can be accessed at https://www.chaffeybreeze.com/2017/09/16/gilla-kaplan-sells-9250-shares-of-celgene-corporation-celg-stock.html.
A number of analysts have weighed in on the stock. Mizuho raised their target price on shares of Celgene Corporation from $134.00 to $158.00 and gave the company a “buy” rating in a research report on Friday. Royal Bank Of Canada assumed coverage on shares of Celgene Corporation in a research report on Thursday. They issued a “top pick” rating and a $176.00 target price on the stock. Bank of America Corporation restated a “buy” rating on shares of Celgene Corporation in a research report on Wednesday. Cowen and Company restated a “buy” rating and issued a $150.00 target price on shares of Celgene Corporation in a research report on Tuesday. Finally, Vetr lowered shares of Celgene Corporation from a “buy” rating to a “hold” rating and set a $145.17 target price on the stock. in a research report on Wednesday, September 6th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating, twenty-one have given a buy rating and one has assigned a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $149.34.
Institutional investors have recently modified their holdings of the stock. Thompson Davis & CO. Inc. increased its stake in shares of Celgene Corporation by 5.9% in the 2nd quarter. Thompson Davis & CO. Inc. now owns 773 shares of the biopharmaceutical company’s stock worth $100,000 after acquiring an additional 43 shares in the last quarter. Harel Insurance Investments & Financial Services Ltd. bought a new position in shares of Celgene Corporation in the 1st quarter worth about $118,000. Motco increased its stake in shares of Celgene Corporation by 19.3% in the 2nd quarter. Motco now owns 981 shares of the biopharmaceutical company’s stock worth $127,000 after acquiring an additional 159 shares in the last quarter. Penserra Capital Management LLC bought a new position in shares of Celgene Corporation in the 2nd quarter worth about $129,000. Finally, Oakworth Capital Inc. increased its stake in shares of Celgene Corporation by 60.9% in the 1st quarter. Oakworth Capital Inc. now owns 1,089 shares of the biopharmaceutical company’s stock worth $136,000 after acquiring an additional 412 shares in the last quarter. Institutional investors own 79.43% of the company’s stock.
About Celgene Corporation
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.